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Abstract: The crystal form is one of the preferred formulations for biotherapeutics, especially thanks
to its ability to ensure high stability of the active ingredient. In addition, crystallization allows the
recovery of a very pure drug, thus facilitating the manufacturing process. However, in many cases,
crystallization is not trivial, and other formulations, such as the concentrate solution, represent the
only choice. This is the case of anti-cluster of differentiation 20 (anti-CD20), which is one of the most
sold antibodies for therapeutic uses. Here, we propose a set of optimized crystallization conditions
for producing anti-CD20 needle-shaped crystals within 24 h in a very reproducible manner with
high yield. High crystallization yield was obtained with high reproducibility using both hanging
drop vapor diffusion and meso batch, which is a major step forward toward further scaling up the
crystallization of anti-CD20. The influence of anti-CD20 storage conditions and the effect of different
ions on the crystallization processes were also assessed. The crystal quality and the high yield allowed
the first crystallographic investigation on anti-CD20, which positively confirmed the presence of the
antibody in the crystals.
Keywords: anti-CD20; crystallization; X-ray diffraction
1. Introduction
Monoclonal antibodies (mAbs) were approved as biopharmaceuticals in 1986 and sales of the
top antibody drugs reached $80 billion in 2017 [1]. These mAbs can be easily expressed in a large
amount; however, a large quantity of protein is lost due to the purification steps [2]. Therefore, the
development of new purification strategies able to reduce protein loss and production costs is strongly
encouraged by the biopharmaceutical industry [3,4]. Crystallization is a well-proven, robust, and
scalable process usually applied to the purification of small molecules [5]. Batch and vapor diffusion
represent the most known crystallization methods. The main difference between these two methods is
represented by the evolution of precipitant and protein concentrations during the experiment; in the
case of batch, these concentrations can be considered constant during each step of the crystallization,
while they usually evolve toward higher values in the case of vapor diffusion. For this reason, the
batch method is considered more reproducible than vapor diffusion, a feature that, along with the
possibility of processing a large quantity of protein, makes batch crystallization the preferred one
for large-scale applications. Nevertheless, vapor diffusion still remains an efficient method to screen
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crystallization conditions using a low quantity of protein. Regardless of the method, crystallization is
potentially able to reduce downstream manufacturing costs by improving the efficiency of the protein
purification step with respect to conventional chromatographic methods [5–11]. Moreover, the active
ingredient is usually more stable in crystal form than in solution, a feature that is crucial in the case of
samples that easily degrade, such as protein molecules. Unfortunately, crystallization is not a trivial
process and, in the case of biomacromolecules that are particularly recalcitrant to forming ordinate
solid state, it is even more complicated. Particularly, in the case of mAbs, Fab and Fc domains are
connected by flexible loops that make the whole antibody structure very flexible and, thus, not suitable
for crystallization. Indeed, the few intact mAb crystal structures available in the Protein Data Bank
(PDB) show very high thermal factors for the Fab–Fc connecting loops (mAb231 having PDB code
1IGT and mAb61.1.3 having PDB code 1GIY) and, at worst, they are missed due to poor electron
density (IgG1b12 having PDB code 1HZH) [12–15]. Such evidence suggests that these intact mAbs are
made by a continuum of conformations sampled by each protein unit in the crystals. The presence of
exposed negatively charged residues on the complementarity-determining region [16] or the presence
of favored Fc–Fv interactions appear to increase the probability of obtaining crystals [17]; however,
unfortunately, only very limited antibodies show such structural features.
Anti-cluster of differentiation 20 (anti-CD20) was the first monoclonal antibody approved for
therapeutic use [18,19]. One of the most known marketed anti-CD20 drugs, rituximab, is a chimera
protein made of a human immunoglobulin G1 (IgG1) constant region and a murine variable region able
to bind to the transmembrane CD20 protein [20]. It is mostly used in autoimmune diseases therapy
and it is effective against CD20-expressing non-Hodgkin’s lymphoma, although it is not curative [18].
Similarly to other antibodies, the high production costs of anti-CD20 ($4000/g) [21] are mainly due
to the usage of traditional purification methods such as protein-A chromatography, which is very
effective in mAb recovery but very expensive due to the high cost of protein-A [22,23]. Conversely,
crystallization is more cost-effective because it does not require expensive chemicals, while keeping the
same purity level of chromatography [24]. Several conditions and protocols to produce anti-CD20
crystals were already reported [25,26], but an extensive investigation on its crystallization conditions
and the effect of the protein storage conditions on the crystallization is yet to be described. In addition,
the crystallographic characterization of anti-CD20 crystals remained elusive until now.
Here, we show the first systematic study of anti-CD20 crystallization, through which sulfate emerges
as the anion of choice for the precipitation of this mAb. In addition to vapor diffusion mode, crystallization
conditions of anti-CD20 were adapted to batch mode. Considering that batch is one of the preferred
crystallization methods for large-scale application, our results could significantly contribute to the
development of anti-CD20 crystallization for industrial applications. Finally, the diffraction quality of
anti-CD20 crystals enabled X-ray diffraction experiments and the first crystallographic characterization of
the antibody, an important step toward the unraveling of its full-length crystal structure.
2. Materials and Methods
2.1. Anti-CD20 Crystallization Experiments
Anti-CD20 monoclonal antibody was provided by FUJIFILM Diosynth Biotechnologies
(Billingham, UK) in 25 mM sodium citrate at pH 6.5, as well as 154 mM sodium chloride solution at
a high level of purity (>98% HPLC, >95% SDS-PAGE). Sodium sulfate anhydrous (purity ≥99.99%),
ammonium sulfate (purity ≥99.0%), lithium sulfate (purity ≥99.99%), tetramethyl ammonium sulfate
(purity ≥99.0%), aluminum sulfate (purity ≥99.99%), potassium sulfate (purity ≥99.0%), magnesium
sulfate (purity ≥99.99%), PEG400, HEPES (purity ≥99.5%), and NaOH (purity ≥98%) from Sigma
were used without further purification to prepare crystallization solutions. Distilled water was
used. Anti-CD20 was thawed on ice for 2–3 h before buffer exchanging against HEPES 100 mM
pH 6.8–8.2 (pH adjusted by NaOH) using an Amicon Ultra centrifugal filter tube (cut-off 30 kDa)
at 7000× g and 4 ◦C. Anti-CD20 concentration was determined by measuring protein absorbance at
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280 nm with a Microvolume ultraviolet–visible light (UV–Vis) spectrophotometer NanoDrop One
(MW = 144.488 kDa, extinction coefficient at 280 nm = 237,380 M−1·cm−1). Crystallization solutions
were made by dissolving sulfate salts in the buffer solution with PEG400. All solutions used in
crystallization tests were filtered through a 0.22-µm Syringe Filter Unit (Sartorius, Germany).
A systematic crystallization optimization was performed based on successful crystallization
conditions. Concentrations of protein, precipitant, and PEG were varied by changing the starting
condition from 2% to 10%, and various pH and temperature values were tested. Nucleation and crystal
growth were recorded under a microscope for the best crystallization conditions.
In hanging drop crystallization experiments, drops made of 2 µL of precipitant solution and 2 µL
of protein solution were equilibrated in a sealed well against 0.5 mL of the same precipitant solution
used as a reservoir. Then, 24-well XRL plates (100) along with siliconized cover slips from Molecular
Dimension were used for these experiments. Drops were manually set.
In the case of the batch method, the final volume solution ranged between 0.4 and 1 mL in
a 1–2 mL Eppendorf tube, by keeping constant the protein solution and crystallization cocktail
volume ratio. The solution in the Eppendorf tube was shaken on a platform at 100 rpm for 5 min.
All crystallization solutions, whether using the hanging drop method or batch method, were put in a
vibration-free refrigerator at 20 ◦C, and all the crystallization experiments were repeated with at least
12 hanging drops.
2.2. Analysis of Anti-CD20 Crystals
Crystals obtained from crystallization experiments were washed to remove protein in solution
with a Costar® Spin-X® centrifuge tube filter (0.22-µm pore size). The washing solution was made
of HEPES, Na2SO4, and PEG400, whose concentration was optimized to avoid crystal solubilization.
Washed crystals were solubilized using 10 mM Tris-HCl, 150 mM NaCl, and pH 8.0, and analyzed by
size-exclusion chromatography (SEC) and SDS-PAGE electrophoresis to check the presence of protein.
SEC was performed using an Enrich650 BIORAD column equilibrated with three column volumes of
elution buffer made of 10 mM Tris-HCl, 150 mM NaCl, and pH 8.0.
2.3. Mass Spectroscopy
SDS-PAGE gel bands of washed crystals obtained in reducing condition were analyzed by mass
spectroscopy in MS/MS mode, to get information on the fragment ion spectrum. The digested mixture
was separated by chromatography prior to mass spectroscopy. The peptide mass fingerprint was used
to identify the protein primary sequence using the Mascot search engine (Supporting Materials).
2.4. X-ray Diffraction Analysis
Anti-CD20 crystals were analyzed by X-ray diffraction at the Diamond Light Source synchrotron
(Didcot, UK) at beamline I04 and at the ESRF synchrotron (Grenoble, France) at beamline ID29. As single
crystals were not of sufficient size and their density was too high to allow fishing, we collected a part
of the sample using a standard cryo-loop, which was mounted on the goniometer and flash-cooled by
liquid nitrogen. As crystals did not diffract at high resolution, the experimental set-up was adapted
to collect low-resolution signals. Therefore, the smallest-radius beamstop was used, along with a
very-low-energy beam (6 keV in the case of Diamond and 7 keV in the case of ESRF) and the highest
sample-to-detector distance available at the beamline. Additionally, 100% transmittance and 10 s of
exposure time were used to increase ring intensity. By using this set-up, well-separated Debye–Scherrer
rings at very low resolution (>40 Å) could be observed. The DAWN program was used to mask and
azimuthally integrate diffraction images to produce powder diffraction profiles [27]. For comparison,
powder diffraction profiles from existing intact mAb crystal structures were calculated using the
program Mercury v.2.9 [28], and compared using the program RootProf [29].
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3. Results
3.1. Anti-CD20 Crystallization and Crystal Analysis
Several published anti-CD20 crystallization cocktails were tested, and protein crystallization
only occurred with the cocktail containing PEG400, Na2SO4, and HEPES [25,26,30]. In addition to
published conditions, screenings from Hampton Research (SaltRX, Index, and PEG/ION1&2) and from
Molecular Dimension (Wizard 1&2, Wizard 3&4, JCSG, and PACT) were performed, but no protein
crystal was observed.
By systematically optimizing the composition of this crystallization cocktail and the protein
concentration, we found that 20–60 mg/mL of anti-CD20, 0.6–1.5 M Na2SO4, and 8–12% (w/v) PEG400
represent the ranges within which anti-CD20 crystallizes via vapor diffusion in the hanging drop
set-up. Additionally, 0.1 M HEPES at a pH ranging between 6.8 and 8.1 is required as a buffer for
the crystallization cocktail and protein solution. Regardless of the concentrations, this condition
allows crystallizing the anti-CD20 protein as a microcrystalline powder. In order to obtain enough
microcrystalline powder to characterize the sample, crystallization conditions were adapted to batch
mode at the meso scale (see Section 3.6 for details). After exhaustive washing, anti-CD20 crystals were
dissolved and analyzed by SEC, which showed a comparable retention time for the main peak obtained
from crystals and anti-CD20 pristine solution (Supplementary Materials, Figure S1). SDS-PAGE
electrophoresis of the main peak fraction showed a clear band at a molecular weight (MW) close to that
expected for the intact anti-CD20 protein (MW = 144 kDa), and tandem mass spectrometry (MS/MS)
performed on this band after trypsin digestion confirmed the presence of anti-CD20 (Supplementary
Materials, Table S1). Apart from the main peak, SEC showed a small peak around 11 mL; such a
peak was also present in the case of the anti-CD20 pristine solution and is likely related to protein
aggregation. However, its area was not significant, being less than 7% of the area of the main peak.
3.2. Crystallographic Analysis of Anti-CD20 Crystals
X-ray diffraction analysis was performed on the optimized anti-CD20 crystals obtained by batch
mode (crystallization conditions provided in Section 3.6), to confirm that crystals were not salts,
but made by proteins in crystal form. First attempts to obtain single-crystal diffraction patterns from
the largest crystals with a micro-focused X-ray beam were unsuccessful. A detectable diffraction signal
was instead obtained using many crystals under the X-ray beam, mimicking a microcrystalline powder
sample. The simultaneous diffraction of randomly oriented microcrystals produced diffraction rings at
66 Å, 57 Å, and 45 Å (Figure 1), detected by an experimental set-up optimized for very-low-resolution
data. We collected diffraction data from several anti-CD20 powder samples obtained using batch
mode and a similar crystallization cocktail; interestingly, diffraction images always contained the
same diffraction rings, suggesting that they represent the signature of anti-CD20 crystals grown in
these conditions.
Even if such diffraction rings were not enough to determine the crystal structure, they could
be exploited to assess the presence of macromolecules in the crystal, containing information about
the crystal packing. The occurrence of characteristic rings at very low resolution, as in Figure 1,
is a peculiar feature of crystal samples having a large unit cell, such as crystals of macromolecules.
Another peculiarity of powder samples with a large unit cell is the huge overlap of diffraction peaks
along the 2θ axis, which increases at higher resolution (see Supplementary Materials for details).
In protein samples, diffraction data resolution is also limited by the atomic thermal motion, which is
larger than in small-molecule samples. All these features are consistent with those observed in Figure 1,
where no rings appear at a resolution higher than 45 Å, thus confirming that crystals were made
by macromolecules.
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the detector, and subjected to azimuthal integration, to produce a powder diffraction pattern along 
the radial direction, as shown in Figure 2. The three rings produced sharp peaks in the powder 
diffraction profile, which emerged from the background. Their 2θ values, which depend on the 
X-ray energy used, represent the fingerprinting of our anti-CD20 crystal samples. 
 
Figure 2. Anti-CD20 diffraction image. Noisy and dead detector pixels were masked by choosing 
proper threshold cut-offs (left), and image intensities were azimuthally integrated to produce a 
one-dimensional powder diffraction pattern (right). 
The few known crystal structures of whole mAbs are listed in Table 1, together with their 
crystallographic parameters and sequence identity with anti-CD20. They were used to calculate the 
powder diffraction profiles at the same wavelength as used in our diffraction analysis (λ = 2.06642 
Å), which showed characteristic peaks in the same 2θ region of our samples (Figure 3). Figure 3 
clearly shows that the high-resolution limit of the region populated by diffraction peaks was 
Figure 1. X-ray diffraction images of optimized anti-cluster of differentiation 20 (CD20) crystal powder
obtained in the same crystallization conditions (60 mg/mL of antibody, 770 mM sodium sulfate,
and 24 wt.% PEG400 in batch set-up) collected at Diamond Light Source (a) and ESRF (b) synchrotrons,
using primary X-ray beams at 6 keV and 7 keV, respectively. The data resolution of the diffraction
rings is shown. The uneven ring intensity in Figure 1b can be ascribed to the non-uniform orientation
of crystallites.
Experimental diffraction patterns were masked to correct for dead regions and noisy pixels in the
detector, and subjected to azimuthal integration, to produce a powder diffraction pattern along the
radial direction, as shown in Figure 2. The three rings produced sharp peaks in the powder diffraction
profile, which emerged from the background. Their 2θ values, which depend on the X-ray energy used,
represent the fingerprinting of our anti-CD20 crystal samples.
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Figure 2. Anti-CD20 diffraction image. Noisy and dead detector pixels were masked by choosing
proper threshold cut-offs (left), and image intensities were azimuthally integrated to produce a
one-dimensional powder diffraction pattern (right).
The few known crystal structures of whole mAbs are listed in Table 1, together with their
crystallographic parameter and sequence identity with anti-CD20. They wer used to calculate the
powder diff ction rofiles at the same wav length as used i our diffraction analysis (λ = 2.06642 Å),
which showed characteristic peaks in the same 2θ region of our samples (Figure 3). Figure 3 clearly
shows t at the high-resolution limit of the region populated by diffraction peaks was consistently
shifted toward lower 2θ values as the cell volume increased (from the bottom to the top). I ter stingly,
Crystals 2019, 9, 230 6 of 13
the number and relative intensity of diffraction peaks from our crystals resembled those of the crystal
structure 1HZH, which had the highest sequence identity with anti-CD20. This PDB-deposited
structure is related to the human antibody IgG1 b12, which recognizes the CD4-binding site of human
immunodeficiency virus-1 (HIV-1) gp120 [14,15]. The large volume of its crystal cell is due to the high
crystallographic symmetry (space group H 3 2), which is able to accommodate 18 copies of the intact
mAb in the unit cell. In the case of 1HZH, diffraction peaks were shifted at lower 2θ with respect
to those of anti-CD20, a difference that could arise from the different unit cell parameters of the two
crystals. The fact that anti-CD20 and 1HZH have similar powder diffraction profiles (same number of
low-resolution peaks with same relative intensities) could suggest that their crystal structures have the
same crystal packing and mAb conformation in the asymmetric unit. In this hypothesis, crystal cell
parameters compatible with the anti-CD20 experimental powder diffraction pattern could be obtained
(details are shown in the Supplementary Materials). Such a calculation showed that the position of
the three peaks in the anti-CD20 experimental powder diffraction profile would coincide with those
of the profile calculated from 1HZH if anti-CD20 had a hexagonal crystal cell with parameters (229,
229, 171) Å, corresponding to a crystal cell volume of 7,795,923 Å3 and a volume per atom of 40.7 Å3.
A comparison with the values reported in Table 1 indicated that these values are fully plausible for an
intact mAb crystal structure.
Table 1. Properties and crystallographic parameters of known crystal structures of intact monoclonal
antibodies (mAbs). CD20—cluster of differentiation 20.
1IGT [12] 1IGY [13] 5DK3 [31] 1HZH [14,15]
mAb type IgG1 IgG1 IgG4 IgG1
Organism Mus musculus Mus musculus Human Human
Sequence identity with anti-CD20 (%) 60 64 83 87
Space group P 1 P 21 P 212121 H 3 2
Crystal cell parameters (Å) 65.8, 76.8, 100.6 66.7, 190.7, 73.1 63.8, 110.8, 265.0 271.3, 271.3, 175.2
Crystal cell volume (Å3) 503,852 874,767 1,874,401 11,168,087
Volume per atom (Å3) 48.3 42.7 43.6 58.3
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Figure 3. Powder diffraction profiles calculated at the same wavelength (2.06642 Å) from the crystal
structures of whole monoclonal antibodies (mAb) currently present in the Protein ata Bank, listed in
Table 1, which were ordered acc ing to the crystal cell volume, going from bottom (smaller volume)
to top (larger volume). Dashed lines indicate the 2θ values of the diffraction peaks found in powder
diffraction profiles from anti-CD20 crystals.
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3.3. Crystal Morphological Analysis
Visible light microscopy was used to monitor anti-CD20 crystallization experiments. In the vapor
diffusion hanging drop experiment, crystal growth preferentially occurred at the interface between the
glass slide and the crystallization solution and resulted in bent needle-shaped crystals 1–2 µm wide
and 10–50 µm long (Figure 4). The condition able to produce the largest crystals in the shortest time
(1–2 days) along with the highest crystal density (up to 1 crystal/µm2) was represented by 30 mg/mL
anti-CD20 in the presence of a crystallization cocktail made of 1.1 M Na2SO4, 12% (w/v) PEG400, and
0.1 M HEPES at pH 7.7 (Figure 4a). Such a condition was able to produce crystals with this morphology
with a reproducibility >95%. It should be taken into account that the concentration of each chemical in
the crystallization cocktail was nominal, because the solution resulted in liquid–liquid phase separation
(LLPS). LLPS disappeared upon mixing the protein and crystallization cocktail and it formed again
before or simultaneously with crystal growth (gray circles in Figure 4b). By increasing Na2SO4 and
PEG400 to 1.5 M and 15% (w/v), respectively, the crystal size significantly reduced, while lower PEG400
and Na2SO4 concentrations (Figure 4b,c) were detrimental both for crystal density and the time of the
appearance of the crystals (crystallization occurred in one week). The lowest concentrations of PEG400
or Na2SO4 at which crystallization was observed were 8% and 0.6 M, respectively. In this case, crystals
appeared after two weeks, and the density of the crystals was the lowest observed.
Crystals 019, 9, x FOR PEER  8 of 14 
 
 
Figure 4. Visible microscopy images of anti-CD20 crystals obtained through hanging drop vapor 
diffusion after seven days of equilibration. Crystals were obtained using 30 mg/mL anti-CD20 and a 
crystallization solution containing (a) 1.1 M Na2SO4 and 12% (w/v) PEG400, (b) 1.1 M Na2SO4 and 8% 
(w/v) PEG400, (c) 0.9 M Na2SO4 and 12% (w/v) PEG400, and (d) 0.9 M Na2SO4 and 8% (w/v) PEG400. 
Crystallizing solutions were buffered by 0.1 M HEPES at pH 7.7. Phase separation is shown by a gray 
circle in (b). 
3.4. Effect of Storage Conditions on Anti-CD20 Crystallization 
Antibodies were reported to be stable at 4 °C for weeks [32–34]. These conditions may not affect 
antibody functions, but they could alter the protein (particularly with respect to the aggregation or 
the conformational state) and, thus, the crystallization process [35]. With the aim of investigating the 
effect of storage conditions (temperature and time) on anti-CD20 crystallization, the protein solution 
underwent to several thawing/storage cycles before the crystallization experiment: (i) thawing–
storage (−80 °C, seven days)–thawing; (ii) thawing–storage (−80 °C, seven days)–thawing–storage 
(−80 °C, seven days)–thawing; (iii) thawing–storage (4 °C, seven days); (iv) thawing–storage (4 °C, 14 
days); (v) thawing–storage (20 °C, seven days); and (vi) thawing–storage (20 °C, 14 days). 
Crystallization tests were performed using 30 mg/mL anti-CD20 and a crystallization solution made 
of 0.9 M Na2SO4, 12% (w/v) PEG400, and 0.1 M HEPES at pH 7.7. Regardless of the storage 
conditions, needle-shaped crystals having similar sizes appeared after two days of equilibration 
against the reservoir (Figure 5). This indicates that storage conditions had a limited effect on the 
anti-CD20 crystal morphology. Conversely, a lower density of crystals was observed as time and 
temperature of storage increased. This result was expected because longer storage time usually has a 
detrimental effect on protein folding and homogeneity, which results in increased energy to form 
crystals, thus reducing the chances of crystallization [36,37]. This effect was magnified in the 
presence of a high storage temperature. Adding glycerol usually allows preserving the protein, 
particularly in the case of storage at low temperature; however, in our case, no effect on the 
crystallization results was observed by adding up to 20% glycerol. 
Figure 4. Visible microscopy images of anti-CD20 crystals obtained through hanging drop vapor
diffusion after seven days of equilibration. Crystals were obtained using 30 mg/mL anti-CD20 and a
crystallization solution containing (a) 1.1 M Na2SO4 and 12% (w/v) PEG400, (b) 1.1 M Na2SO4 and 8%
(w/v) PEG400, (c) 0.9 M Na2SO4 and 12% (w/v) PEG400, and (d) 0.9 M Na2SO4 and 8% (w/v) PEG400.
Crystallizing solutions were buffered by 0.1 M HEPES at pH 7.7. Phase separation is shown by a gray
circle in (b).
3.4. Effect of Storage Conditions on Anti-CD20 Crystallization
Antibodies were reported to be stable at 4 ◦C for weeks [32–34]. These conditions may not affect
antibody functions, but they could alter the protein (particularly wit respect to the aggregation or
the c nforma al state) and, thus, the crystallization pro ess [35]. With th aim of investi ng the
effect of storage conditions (temperature and t me) on anti-CD20 crys allization, the protein solu ion
underwent to several hawing/storage cycles before the crystallization experiment: (i) thaw g–storage
(−80 ◦C, seven days)–tha ing; (ii) thawing–storage (−80 ◦C, even days)–thawing–storage (−80 ◦C,
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seven days)–thawing; (iii) thawing–storage (4 ◦C, seven days); (iv) thawing–storage (4 ◦C, 14 days);
(v) thawing–storage (20 ◦C, seven days); and (vi) thawing–storage (20 ◦C, 14 days). Crystallization
tests were performed using 30 mg/mL anti-CD20 and a crystallization solution made of 0.9 M Na2SO4,
12% (w/v) PEG400, and 0.1 M HEPES at pH 7.7. Regardless of the storage conditions, needle-shaped
crystals having similar sizes appeared after two days of equilibration against the reservoir (Figure 5).
This indicates that storage conditions had a limited effect on the anti-CD20 crystal morphology.
Conversely, a lower density of crystals was observed as time and temperature of storage increased.
This result was expected because longer storage time usually has a detrimental effect on protein folding
and homogeneity, which results in increased energy to form crystals, thus reducing the chances of
crystallization [36,37]. This effect was magnified in the presence of a high storage temperature. Adding
glycerol usually allows preserving the protein, particularly in the case of storage at low temperature;
however, in our case, no effect on the crystallization results was observed by adding up to 20% glycerol.
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Figure 5. Visible light microscopy images of anti-CD20 crystals obtained through hanging drop vapor
diffusion after seven days. (A1,A2) show crystals obtained using protein which underwent to one
and two cycles of thawing/storage (−80 ◦C, seven days), respectively. (B1,B2) are related to crystals
obtained using a single cycle of thawing/storage at 4 ◦C for seven and 14 days, respectively. (C1,C2)
differ from (B1,B2) in storage temperature only (20 ◦C).
3.5. Influence of Ions on mAb Crystallization
Our results point out sodium sulfate as the best precipitant to trigger anti-CD20 crystallization
among the tested salts. Ion effectiveness toward protein precipitation increases with ion valence; thus,
the sulfate anion is expected to be more important than the sodium cation in the salting-out process
of anti-CD20. Nevertheless, the crystallization/precipitation process could significantly benefit from
changing the counterion. Sodium, lithium, ammonium, magnesium, potassium, aluminum, and zinc
sulfate salts, which represent the sulfate salts commonly used in protein crystallization, were tested as
anti-CD20 precipitants in the presence of 12% (w/v) PEG400 and 0.1 M HEPES at pH 7.7. The maximum
allowed concentration was very low in the case of potassium and aluminum sulfate due to their poor
solubility in the presence of PEG400 and slightly basic pH; therefore, these salts were used at saturated
concentration and no scanning of concentration was performed as in the case of other salts.
Results show that needle crystals appeared only in the case of sodium, lithium, and ammonium
sulfate (Table 2); lithium and sodium were effective at 1.0 M, while a higher concentration was required
in the case of ammonium (1.5 M). This result is not in agreement with the Hofmeister series, where the
ammonium cation appears a better precipitant for protein than lithium and sodium. We speculate
that such unexpected behavior is related to the different partitioning of these ions in the two forming
phases of the LLPS. By using EPIsuite [38], we calculated that ammonium logP was about four
units lower than that of sodium and potassium ions (logPNH4+ = −4.37, logPNa+ = logPLi+ = −0.77).
These values suggest that salt concentration at equilibrium could be different in the two phases,
although the same concentration of each sulfate salt was used to prepare the pristine crystallization
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cocktail. The Hofmeister series compare ions with the same concentration; thus, its predictive power
in such a complicated solution environment is poor.
No crystallization/precipitation was observed using magnesium, zinc, aluminum, and potassium
sulfate salts, regardless of concentration. It should be noted that, in the case of potassium, the absence
of protein precipitation is most likely related to the low salt concentration rather than its poor ability in
protein precipitation, which, according to the Hofmeister series, is second only to ammonium among
the tested salts.
Regarding crystallization time, at 1.5 M of salt, crystals appeared at a shorter time in the
case of ammonium sulfate (~3 days) than in the case of sodium (~5 days) and lithium (~7 days).
Usually, crystal size increases as nucleation time reduces; however, in our case, crystal size decreased
from sodium to ammonium and lithium. Moreover, no crystals/precipitate appeared after two months
at a lower tested salt concentration (0.5 M).
Table 2. Results of anti-CD20 crystallization after seven days using several sulfate salts at
different concentrations.
Salt
Salt Concentration
0.5 M 1.0 M 1.5 M
Na2SO4 Clear drop Needle-like crystals Needle-like crystals
Li2SO4 Clear drop Needle-like crystals Needle-like crystals
(NH4)2SO4 Clear drop Clear drop Needle-like crystals
MgSO4 Clear drop Clear drop Clear drop
ZnSO4 Clear drop Clear drop Clear drop
3.6. Meso Batch Crystallization
Our experiments identified a cocktail of chemicals suitable for crystallizing anti-CD20 in a very
reproducible way using the vapor diffusion method. Such a result represents a valuable starting point
to optimize anti-CD20 crystallization for set-ups that are usually preferred for large-scale processes.
Particularly, in the case of batch mode, the concentration of each chemical is constant and instantly
reached after mixing the protein and crystallization cocktail [39], unlike vapor diffusion where it
continuously changes up to the equilibrium value. In order to optimize the crystallization conditions
for batch mode, crystallization experiments of anti-CD20 using a final batch volume ranging from
400 µL to 1 mL were performed. Anti-CD20 crystals appeared using 60 mg/mL antibody, 770 mM
sodium sulfate, and 24 wt.% PEG400 in the batch set-up (Figure 6). Such optimized conditions allow
significantly reducing the time in which crystals appear (within 12 h) with respect to the vapor diffusion
set-up (within 2–3 days). In this case, crystals appeared smaller than when using vapor diffusion
and reached the maximum size within 12 h. However, the batch mode appeared detrimental for
the density of crystals with respect to vapor diffusion and resulted in more pronounced LLPS than
in the case of vapor diffusion. Because interface surface and phase dispersion significantly differ
in the case of quiescent and non-quiescent crystallization, we compared the result of crystallization
under stirring/shaking and static conditions. We observed that crystallization occurred in a similar
manner in both cases, but stirring/shaking resulted in a larger quantity of amorphous precipitation,
thus reducing crystallization yield. Such a result suggests that the interface process is important in the
precipitation/crystallization of anti-CD20, as already observed using the vapor diffusion set-up. This is
in agreement with many crystallization studies of mAbs [40–42]. Particularly, conditions close to the
critical point of the meta stable LLPS promote crystal nucleation or precipitation because, in these
conditions, crystal nuclei are surrounded by a liquid-like layer able to reduce interfacial free energy,
thus resulting in faster nucleation [43].
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Figure 6. Visible light microscopy images of anti-CD20 crystals obtained using batch mode: (a) after
three days under static conditions, and (b) after the seventh day under stirring conditions.
4. Discussion
Among the physical forms in which drugs can be provided for final user use, the crystal form is
one of the preferred because it ensures high stability and a high purity level of the active ingredients.
However, particularly in the case of protein-based drugs, crystallization is not straightforward,
especially at the industrial level. This is the case of anti-CD20, the first antibody sold for clinical use,
for which we observed a low reproducibility of the published crystallization condition in our labs. It is
worth noting that such a lack of reproducibility of published anti-CD20 crystallization conditions was
already observed in literature [44], suggesting that the mechanism is not clear and the crystallization
process is very sensitive to small deviations of relevant variables. As an example, we observed that
the phosphate salts and phosphate-buffered saline (PBS), suggested in Reference [26] as a precipitant
for efficient anti-CD20 crystallization, resulted in a clear drop. Similarly, calcium acetate, along with
PEG 1K and imidazole [30] led to salt crystal aggregates. Our experiments also showed that some
crystallization cocktails reported in the literature could not be prepared, because concentrations of the
cocktail components were over the solubility in that condition (e.g., the cocktail containing sodium
sulfate and PEG400 in Reference [30]). Therefore, starting from crystallization cocktails reported in the
literature, extensive optimization was required to get anti-CD20 crystals in a reproducible way in our
labs. Initially, we focused on the vapor diffusion crystallization method and found that the sulfate anion
is required for anti-CD20 crystallization along with PEG400 and a pH between 6.8 and 8.1. This could
be the consequence of the very narrow crystallization window we found for anti-CD20 in the presence
of such a cocktail, particularly in the case of sodium sulfate. In addition, at the concentration required
for crystallization, PEG400 and sodium sulfate resulted in LLPS formation, and, in the presence of
such phase separation, it got more difficult defining the true concentration of the chemicals in the
phase where crystals appear. Our condition to produce largest crystals in the shortest time and with
the highest density (Figure 4a) appears slightly different from that previously reported [30] (sodium
sulfate concentrate reduced from 1.36 M to 1.1 M; HEPES 0.1 M at pH 7.7 is used instead of Tris 0.1 M
pH 7.5; 30 mg/mL anti-CD20 is used instead of 20); however, very importantly, it allows producing
crystals in the absence of the seeding procedure, which was necessary in the reported condition.
Once optimized, the sulfate salt/PEG400 condition provided crystals of needle shape having
a width of ~2 µm and a length of up to 50 µm, using the vapor diffusion hanging drop set-up;
crystallization occurred only in the presence of sodium, lithium, or ammonium sulfate. The storage
time and temperature were found to affect anti-CD20 crystallization; indeed, as storage time increased
from seven to 14 days and temperature from −80 ◦C to 20 ◦C, a lower number of crystals were obtained
by keeping constant the cocktail composition. Finally, the crystallization cocktail able to produce
larger crystals in a shorter time through vapor diffusion was optimized for batch at the meso scale.
After mixing the protein solution and crystallization cocktail, the final concentrations of PEG400
and protein were 12% (w/v) and 30 mg/mL, respectively. These values are in agreement with those
at equilibrium in the case of the vapor diffusion mode. Interestingly, sodium sulfate concentration
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was much lower than expected, being about three times lower (385 mM) than the concentration
at equilibrium in vapor diffusion (1.1 M). Batch crystallization provided crystals having the same
morphology as those obtained through vapor diffusion, but in a shorter time (12 h vs. 2–3 days in
the case of vapor diffusion) and having a smaller size. In this case, the quantity of powder crystal
was large enough to prepare a sample for X-ray powder diffraction analysis. By analyzing the X-ray
diffraction patterns, we observed that the resolution of the diffraction rings and their spacing were
compatible with protein only and not salt. This result represents the first direct evidence of the presence
of anti-CD20 in crystal form, since, until now, anti-CD20 crystals were analyzed only using techniques
unable to distinguish between protein in solution, in amorphous or in crystal form [25].
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4352/9/5/230/s1,
Figure S1: Size Exclusion Chromatography for anti-CD20 from washed and dissolved crystals (solid line) and
from pristine solution (dashed line) (a). SDS-PAGE electrophoresis performed on-washed and dissolved crystals
(b); Figure S2: Powder diffraction profiles calculated at the same wavelength (2.06642 Å) from the crystal structure
of (a) sodium citrate (CCDC code 1478189) and (b) Fc fragment of human immunoglobulin G1 (PDB code 3AVE).
Molecules are shown in stick-and-ball (a) and cartoon (b) representations. Diffraction reflections are indicated by
lines below the 2q axis; Table S1: Mascot analysis of peptide fingerprint of digested band from anti-CD20 crystals.
Only the sequence showing the best match with experimental data is shown.
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